Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • Data Privacy
  • Français
  • my CNW 
    • Login
    • Register
  • Client Login 
    • Online Member Centre
    • Next Gen Communications Cloud
    • Cision Communications Cloud®
  • Sign Up
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
Advanced Search
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Canadian Federal Government
      • Canadian Municipal Government
      • Canadian Provincial Government
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

  • Advanced Search
  • Overview
  • Multichannel Amplification
  • Monitoring
  • Distribution
  • Multimedia
  • Guaranteed Paid Placement
  • AI Tools
  • IR
  • Become a Client
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • General Enquiries
  • Media
  • Worldwide Offices
  • Hamburger menu
  • Cision Canada
  • Send a Release
  • FR
    • Phone

    • 877-269-7890 from 8 AM - 10 PM ET

    • ALL CONTACT INFO
    • Contact Cision

      877-269-7890
      from 8 AM - 10 PM ET

  • Send a Release
  • Sign Up
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign Up
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • GDPR
  • Overview
  • Multichannel Amplification
  • Monitoring
  • Distribution
  • Multimedia
  • Guaranteed Paid Placement
  • AI Tools
  • IR
  • Send a Release
  • Sign Up
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • GDPR
  • Become a Client
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • General Enquiries
  • Media
  • Worldwide Offices
  • Send a Release
  • Sign Up
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • GDPR

Lynparza® (olaparib) Receives New Indication for BRCA-Mutated Metastatic Breast Cancer

AstraZeneca (CNW Group/AstraZeneca)

News provided by

AstraZeneca

May 10, 2018, 07:59 ET

Share this article

Share toX

Share this article

Share toX

Lynparza has been shown to reduce the risk of disease progression or death by 42 per cent compared to standard of care chemotherapy.i

MISSISSAUGA, May 10, 2018 /CNW/ - AstraZeneca today announced that Health Canada has approved Lynparza® (olaparib) tablets, as a monotherapy for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer who have been previously treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting. Patients with hormone receptor positive (HR+) breast cancer should have progressed on or be considered inappropriate for endocrine therapy. Germline BRCA mutation must be confirmed before Lynparza treatment is initiated.ii

"The approval of Lynparza for BRCA-mutated metastatic breast cancer represents a significant step for patients with this form of advanced breast cancer as it is the first drug to be available for these specific tumours," said Dr. Karen Gelmon, Professor of Medicine at the University of British Columbia. "By using PARP inhibitors, the treatment is able to target the BRCA-mutated tumour cells and repair the damaged DNA with fewer side effects than currently used chemotherapies, which may be more toxic for patients."

Health Canada's approval of Lynparza for gBRCAm HER2-negative metastatic breast cancer was based on data from the phase III, randomized, open-label, multicentre, active-controlled trial, OlympiAD (Study D0819C00003).iii

The OlympiAD study met its primary objective of demonstrating a statistically significant and clinically meaningful improvement in progression-free survival for Lynparza compared with the chemotherapy comparator arm, reducing the risk of disease progression or death by 42 per cent (HR 0.58; 95% CI 0.43-0.80; p=0.0009; median 7.0 months [95% CI 5.7-8.3] for Lynparza vs. 4.2 months [95% CI 2.8-4.3] for comparator).iv

"Women with metastatic breast cancer want to live the best life they can, for as long as they can. While each has her own reason – to reach a milestone, or to create more memories with her family – enabling more quality time is closely linked to having a toolbox of treatments that control the disease and let them continue to live on," said MJ DeCoteau, founder and executive director of Rethink Breast Cancer. "The approval of Lynparza offers a new, effective option to patients with BRCA-mutated metastatic breast cancer that will help them live a better life longer." 

This is the third approved indication for Lynparza in Canada, first granted marketing authorization with conditions in April 2016, in capsules as monotherapy for the maintenance treatment for patients with platinum-sensitive relapsed BRCA-mutated (germline or somatic) high grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete response or partial response) to platinum-based chemotherapy.v

On May 4, 2018, Health Canada approved Lynparza tablets, as a monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed, high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete response or partial response) to platinum-based chemotherapy. Marketing authorization with conditions was granted for treatment of patients with BRCA wild-type status, pending the results of trials to verify its clinical benefit. The indication also coincides with the approval of a new tablet formulation of Lynparza, which reduces daily pill intake from 16 capsules to four tablets daily.

The most common adverse reactions (≥20%) in the OlympiAD trial for patients who received Lynparza were nausea (58%), anemia (40%), fatigue (including asthenia) (37%), vomiting (30%), neutropenia (27%), leukopenia (25%), diarrhea (21%), and headache (20%). The percentage of patients who discontinued treatment in the Lynparza arm was 5% compared to the chemotherapy arm which was 8%.

About BRCA in Breast Cancer
Breast cancer is the most common cancer among Canadian women.vi It is estimated that 26,300 women and 230 men in Canada were diagnosed with breast cancer in 2017.vii

The risk of developing breast cancer is increased in women with specific inherited genetic abnormalities, including BRCA mutations.viii Women who carry a mutation in their BRCA1 or BRCA2 genes have a 40-85 per cent chance of developing breast cancer in their lifetime, are more likely to develop breast cancer at a younger age (before menopause), and often have multiple family members with the disease.ix This genetic marker indicates an increased risk, but also now offers the possibility of a targeted treatment option for women already diagnosed with germline BRCA-mutated breast cancer.x

About Lynparza (olaparib)
Lynparza was the first Health Canada-approved oral poly (ADP-ribose) polymerase (PARP) inhibitor that may exploit tumor DNA damage response (DDR) pathway deficiencies to potentially kill cancer cells. xi It is the first PARP inhibitor to be approved for treatment of patients with advanced ovarian cancer and BRCA-mutated, HER2-negative metastatic breast cancer.

Health Canada first issued a Notice of Compliance with Conditions for Lynparza capsules in April 2016, which followed the announcement of the approval of Lynparza by the FDA and the European Union in December 2014. In May 2018, Health Canada granted approval for the new tablet formulation of Lynparza for the maintenance treatment of adult patients with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete response or partial response) to platinum-based chemotherapy. For treatment of patients with BRCA wild type status, marketing authorization with conditions was granted, pending the results of trials to verify its clinical benefit.

AstraZeneca is conducting multiple Lynparza phase III studies across a variety of indications and tumour types.

Lynparza is a registered trademark of AstraZeneca AB, used under license by AstraZeneca Canada Inc.

About AstraZeneca
AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialization of primary and specialty care medicines that transform lives. Our primary focus is on three important areas of healthcare: Cardiovascular and Metabolic disease; Oncology; and Respiratory, Inflammation and Autoimmunity. AstraZeneca operates in more than 100 countries and its innovative medicines are used by millions of patients worldwide. In Canada, we employ more than 675 employees across the country and our headquarters are located in Mississauga, Ontario. For more information, please visit the company's website at www.astrazeneca.ca.

i AstraZeneca Canada Inc., Lynparza® (olaparib) Tablets Product Monograph. May 2018

ii Ibid.

iii Ibid.

iv Ibid.

v AstraZeneca Canada Inc., Health Canada approves Lynparza™ for the Treatment of Ovarian Cancer in Patients with BRCA-Mutations. Newswire.ca. May 2016. Accessed April 11, 2018. https://www.newswire.ca/news-releases/health-canada-approves-Lynparza-for-the-treatment-of-ovarian-cancer-in-patients-with-brca-mutations-577929961.html

vi Canadian Cancer Society. Breast Cancer Statistics. Accessed April 11, 2018. Available at: http://www.cancer.ca/en/cancer-information/cancer-type/breast/statistics/?region=bc

vii Canadian Breast Cancer Foundation. Facts & Stats. Accessed April 11, 2018. Available at: http://www.cbcf.org/central/AboutBreastCancerMain/FactsStats/Pages/default.aspx

viii Rethink Breast Cancer. Are you High Risk. Accessed April 11, 2018. Available at: https://rethinkbreastcancer.com/breast-health/what-you-need-to-know/are-you-high-risk/

ix Ibid.

x AstraZeneca Canada Inc., Lynparza® (olaparib) Tablets Product Monograph. May 2018

xi AstraZeneca Canada Inc., Health Canada approves Lynparza™ for the Treatment of Ovarian Cancer in Patients with BRCA-Mutations. Newswire.ca. May 2016. Accessed April 11, 2018. https://www.newswire.ca/news-releases/health-canada-approves-Lynparza-for-the-treatment-of-ovarian-cancer-in-patients-with-brca-mutations-577929961.html

SOURCE AstraZeneca

Stacey Brown, Senior Manager, Corporate Communications, AstraZeneca Canada, Tel: 905-803-5733 ext. 45733, Email: [email protected]; Hibaq Ali, Manager, Integrated Media, Weber Shandwick Canada, Tel: 416.642.7915, Email: [email protected]

Modal title

Organization Profile

AstraZeneca

    Also from this source

  • SOPHiA GENETICS Announces Expanded Collaboration with AstraZeneca to Accelerate Liquid Biopsy Testing Globally from AACR

  • Alexion, AstraZeneca Rare Disease reaches an agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for Koselugo (selumetinib) for the treatment of paediatric patients with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN)

  • ASTRAZENECA CANADA PARTNERS WITH THE LEUKEMIA & LYMPHOMA SOCIETY OF CANADA TO DRIVE CHANGE IN BLOOD CANCER RESEARCH

Contact Cision

  • 866-245-2317
    from 8 AM - 10 PM ET
  • Become a Client
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • General Enquiries
  • Media

Products

  • Cision Communications Cloud®
  • Media Monitoring
  • Content Distribution
  • Multimedia Distribution
  • Measurement & Analytics
  • Investor Relations

About

  • About Cision Canada
  • About Cision
  • Media Partners
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Online Member Centre
  • Next Gen Communications Cloud
  • Cision Communications Cloud®
  • my CNW

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Centre
  • Next Gen Communications Cloud
  • Cision Communications Cloud
  • my CNW
877-269-7890
from 8 AM - 10 PM ET
  • Terms of Use
  • Information Security Policy
  • Site Map
  • Cookie Settings
  • Accessibility Statement
Copyright © 2025 CNW Group Ltd. All Rights Reserved. A Cision company.